Where we’re going
The No Surprises Act and Transparency in Coverage Final Rules: An Enforcement Update
On August 20, 2021, the Health and Human Services, Labor and Treasury Departments released FAQs About Affordable Care Act and Consolidated Appropriations Act, 2021 Implementation Part 49, which delays the enforcement of certain provisions contained in the No Surprises Act and the Transparency in Coverage (“TiC”) Final Rules. The reasons for the various delays include … Continued
The 2020 Olympic Games and Health Care
We are halfway through the 2020 Olympic Games being held in Tokyo, Japan. As I write this, the United States is tied with China for the total number of medals won (46). We’ve witnessed new world records (Caeleb Dressel, Tatjana Schoenmaker, Emma Mckeon) and new sports (karate, surfing, climbing and skateboarding). You may be asking … Continued
Does Part I of the Requirements Related to Surprise Billing Apply to Reference-Based Pricing Plans?
On July 1, 2021, the U.S. Departments of Health and Human Services (HHS), Labor, and Treasury, and the Office of Personnel Management, issued the first set of regulations under the No Surprises Act – “Part I of the Requirements Related to Surprise Billing.”[1] Part I provides regulations for only a portion of the No Surprises … Continued
One Final Time? – The Supreme Court Preserves the Patient Protection and Affordable Care Act
Over the past two years, we’ve followed and discussed the twists and turns in the Patient Protection and Affordable Care Act (the “PPACA”) legal battle.[1] In December 2020, we concluded that the Supreme Court would not overturn the PPACA. We anticipated that the Supreme Court may use the nullified penalty in the individual mandate as … Continued
Healthcare Law in Texas: A $19.1 Million Dollar Jury Verdict and a Petition for Review
In November 2017, ACS Primary Care Physicians Southwest PA and Emergency Services of Texas (affiliates of physician led TeamHealth), filed a lawsuit in Houston, Texas alleging that Molina Healthcare, Inc. and Molina Healthcare of Texas, Inc. failed to pay the usual and customary rates for out-of-network services.[1] ACS and Emergency Services of Texas sought more … Continued
Covid-19’s Effects on Health Insurance: Experiences of Insureds and Insurers
Covid-19 has had sweeping effects across the world, as worldwide, 3.5 million people have died.[1] An estimated 591,000 of these deaths occurred in the U.S.[2] Future impacts on health insurers and insureds are uncertain and difficult to project. While economists are aiming at a moving target, the pandemic will have an estimated 4.5 percent GDP loss, … Continued
AI in Healthcare
In April, Nuance Communications, Inc. announced that it was being acquired by Microsoft for 19.7 billion dollars. This deal is expected to be ongoing throughout the rest of 2021. [1] Microsoft, in this transaction, made sure to emphasize that it wants to provide software that works alongside doctors. [2] Let’s take a look at what … Continued
Power to the Patients – A Hospital Price Transparency Grass Roots Movement
If you did not watch the Academy Awards, you may have missed a new national campaign. It wasn’t about COVID. It wasn’t about the opioid crisis, anti-bullying, or suicide prevention. (https://rpdrlatino.com) It was about medical price transparency – Power to the Patients – “Our Health. Our Money.” The campaign strives to raise awareness that knowing … Continued
Prescription Drug Legislation to Watch in 2021
Prescription drug prices and spending are hot topics and for good reason. U.S. pharmaceutical prices are 2.56 times higher than prices seen in 32 other nations, according to a report released by the Rand Corporation.[1] For brand-named drugs that number multiple jumps to 3.44.[2] Retail prescription drug spending accounted for 10% of the total health … Continued
March-In Rights under the Bayh-Dole Act: Will the Pharmaceutical Industry be Victorious in Obtaining an Express Limitation to Prevent Price Control?
On December 12, 1980, the Bayh-Dole Act was enacted to provide incentives to innovate and promote the commercialization of federally funded inventions and amended the existing patent laws. In December 2002, The Economist published an opinion piece calling the Bayh-Dole Act “innovation’s golden goose” and stating that it was “[p]ossibly the most inspired piece of … Continued